HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA VCRP elimination poses "dilemma" for CIR panel in obtaining ingredient use data.

This article was originally published in The Rose Sheet

Executive Summary

FDA VCRP ELIMINATION POSES "DILEMMA" FOR CIR PANEL as the voluntary safety review group considers how it will attain frequency of use data (the number of products in which an ingredient is used) for cosmetics ingredients, Cosmetic Ingredient Review Chairman Wilma Bergfeld, MD, Cleveland Clinic Foundation, stated. During CIR's May 19 meeting in Washington, D.C., Bergfeld proclaimed that cuts in FDA's cosmetics program including the suspension of the Voluntary Cosmetic Reporting Program, is a "little bit discouraging." She added that "hopefully" the situation "will be resolved" so CIR can obtain the "newest information" available.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS005439

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel